RGH-706 as a Potential Treatment for Hyperphagia in PWS

Study Purpose

RGH-706 is a once-daily oral capsule that has been developed by Gedeon Richter for weight management. The Phase 2 study of RGH-706 will evaluate the efficacy, safety, and tolerability of RGH-706 in people with Prader-Willi syndrome and will measure changes in hyperphagia, body weight, body mass, metabolism, and clinical global impression.

Recruitment Criteria

Study Type: Interventional
Eligible Ages: 17 years and older

See the trial listing at clinicaltrials.gov for a full list of inclusion and exclusion criteria.

Trial Details

ClinicalTrials.Gov Id: NCT05322096
Phase: 2
Duration:  17 weeks
Lead Sponsor: Gedeon Richter Plc
Countries: United States, Czechia, France, Italy, Spain, others to be determined

This study will be available at the following U.S. sites:  

San Diego, CA       
Chicago, IL
Brooklyn, NY
Mineola, NY
New York, NY
Cleveland, OH
Salt Lake City, UT
Other sites to be determined

Questions?

Contact: Gedeon Richter
Medical Information Scientific Service
Email: medinfo@richter.hu